CoChat

Biochemical Assessment of Pheochromocytoma and Paraganglioma

Eisenhofer, Graeme, Pamporaki, Christina, Lenders, Jacques W M · 2023 · Endocrine Reviews
Cited by 116

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

Pheochromocytoma and paraganglioma (PPGL) require prompt consideration and efficient diagnosis and treatment to minimize associated morbidity and mortality. Once considered, appropriate biochemical testing is key to diagnosis. Advances in understanding catecholamine metabolism have clarified why measurements of the O-methylated catecholamine metabolites rather than the catecholamines themselves are important for effective diagnosis. These metabolites, normetanephrine and metanephrine, produced respectively from norepinephrine and epinephrine, can be measured in plasma or urine, with choice according to available methods or presentation of patients. For patients with signs and symptoms of catecholamine excess, either test will invariably establish the diagnosis, whereas the plasma test provides higher sensitivity than urinary metanephrines for patients screened due to an incidentaloma or genetic predisposition, particularly for small tumors or in patients with an asymptomatic presentation. Additional measurements of plasma methoxytyramine can be important for some tumors, such as paragangliomas, and for surveillance of patients at risk of metastatic disease. Avoidance of false-positive test results is best achieved by plasma measurements with appropriate reference intervals and preanalytical precautions, including sampling blood in the fully supine position. Follow-up of positive results, including optimization of preanalytics for repeat tests or whether to proceed directly to anatomic imaging or confirmatory clonidine tests, depends on the test results, which can also suggest likely size, adrenal vs extra-adrenal location, underlying biology, or even metastatic involvement of a suspected tumor. Modern biochemical testing now makes diagnosis of PPGL relatively simple. Integration of artificial intelligence into the process should make it possible to fine-tune these advances.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endrev/bnad011

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 426

  1. Lenders, 2020, Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the working group on endocrine hypertension of the European Society of Hypertension, J Hypertens, 38, 1443, 10.1097/HJH.0000000000002438 · DOI · Paper page
  2. Sbardella, 2020, Pheochromocytoma: an approach to diagnosis, Best Pract Res Clin Endocrinol Metab, 34, 10.1016/j.beem.2019.101346 · DOI
  3. Eisenhofer, 2003, Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results, J Clin Endocrinol Metab, 88, 2656, 10.1210/jc.2002-030005 · DOI · Paper page
  4. Yu, 2010, False positive test results for pheochromocytoma from 2000 to 2008, Exp Clin Endocrinol Diabetes, 118, 577, 10.1055/s-0029-1237699 · DOI · Paper page
  5. Kline, 2020, Very high rate of false positive biochemical results when screening for pheochromocytoma in a large, undifferentiated population with variable indications for testing, Clin Biochem, 77, 26, 10.1016/j.clinbiochem.2020.01.005 · DOI
  6. Mantero, 2000, A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian Society of Endocrinology, J Clin Endocrinol Metab, 85, 637
  7. Kopetschke, 2009, Frequent incidental discovery of phaeochromocytoma: data from a German cohort of 201 phaeochromocytoma, Eur J Endocrinol, 161, 355, 10.1530/EJE-09-0384 · DOI · Paper page
  8. Tufton, 2017, Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers, Clin Endocrinol (Oxf), 86, 286, 10.1111/cen.13246 · DOI
  9. Amar, 2021, International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers, Nat Rev Endocrinol, 17, 435, 10.1038/s41574-021-00492-3 · DOI · Paper page
  10. White, 2022, Tumour detection and outcomes of surveillance screening in SDHB and SDHD pathogenic variant carriers, Endocr Connect, 11, 10.1530/EC-21-0602 · DOI
  11. Kasperlik-Zaluska, 2006, 1,111 Patients with adrenal incidentalomas observed at a single endocrinological center: incidence of chromaffin tumors, Ann N Y Acad Sci, 1073, 38, 10.1196/annals.1353.004 · DOI
  12. Grozinsky-Glasberg, 2010, Clinically silent chromaffin-cell tumors: tumor characteristics and long-term prognosis in patients with incidentally discovered pheochromocytomas, J Endocrinol Invest, 33, 739, 10.1007/BF03346680 · DOI
  13. Rogowski-Lehmann, 2018, Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging, Endocr Connect, 7, 1168, 10.1530/EC-18-0318 · DOI
  14. Neumann, 1993, Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease, N Engl J Med, 329, 1531, 10.1056/NEJM199311183292103 · DOI · Paper page
  15. Eisenhofer, 2001, Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes, J Clin Endocrinol Metab, 86, 1999, 10.1210/jcem.86.5.7496 · DOI · Paper page
  16. Eisenhofer, 1999, Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2, N Engl J Med, 340, 1872, 10.1056/NEJM199906173402404 · DOI · Paper page
  17. Eisenhofer, 2019, Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine, Clin Chim Acta, 490, 46, 10.1016/j.cca.2018.12.019 · DOI
  18. Kline, 2021, Properly collected plasma metanephrines excludes PPGL after false-positive screening tests, J Clin Endocrinol Metab, 106, e2900, 10.1210/clinem/dgab241 · DOI
  19. Pommer, 2022, Preanalytical considerations and out-patient vs in-patient tests of plasma metanephrines to diagnose pheochromocytoma, J Clin Endocrinol Metab, 107, e3689, 10.1210/clinem/dgac390 · DOI
  20. Eisenhofer, 2001, Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma, Rev Endocr Metab Disord, 2, 297, 10.1023/A:1011572617314 · DOI · Paper page
  21. Hortnagl, 1969, Bovine splenic nerve: characterization of noradrenaline-containing vesicles and other cell organelles by density gradient centrifugation, J Physiol, 205, 103, 10.1113/jphysiol.1969.sp008954 · DOI
  22. Laduron, 1968, Tissue fractionation and catecholamines. II. Intracellular distribution patterns of tyrosine hydroxylase, dopa decarboxylase, dopamine-beta-hydroxylase, phenylethanolamine N-methyltransferase and monoamine oxidase in adrenal medulla, Biochem Pharmacol, 17, 1127, 10.1016/0006-2952(68)90048-8 · doi:10.1016/0006-2952(68)90048-8
  23. Schuldiner, 1978, Role of a transmembrane pH gradient in epinephrine transport by chromaffin granule membrane vesicles, Proc Natl Acad Sci U S A, 75, 3713, 10.1073/pnas.75.8.3713 · DOI · Paper page
  24. Henry, 1994, Biochemistry and molecular biology of the vesicular monoamine transporter from chromaffin granules, J Exp Biol, 196, 251, 10.1242/jeb.196.1.251 · DOI · Paper page
  25. Eisenhofer, 2014, Laboratory evaluation of pheochromocytoma and paraganglioma, Clin Chem, 60, 1486, 10.1373/clinchem.2014.224832 · DOI · Paper page
  26. Eisenhofer, 2004, Leaky catecholamine stores: undue waste or a stress response coping mechanism?, Ann N Y Acad Sci, 1018, 224, 10.1196/annals.1296.027 · DOI · Paper page
  27. Kopin, 1964, Storage and metabolism of catecholamines: the role of monoamine oxidase, Pharmacol Rev, 16, 179
  28. Eisenhofer, 1998, Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors, J Clin Endocrinol Metab, 83, 2175, 10.1210/jcem.83.6.4870 · DOI · Paper page
  29. Eisenhofer, 1988, Source and physiological significance of plasma 3,4-dihydroxyphenylalanine in the rat, J Neurochem, 51, 1204, 10.1111/j.1471-4159.1988.tb03088.x · DOI
  30. Eisenhofer, 1994, The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats, J Auton Nerv Syst, 50, 93, 10.1016/0165-1838(94)90127-9 · DOI
  31. Eisenhofer, 2008, Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas, Horm Metab Res, 40, 329, 10.1055/s-2008-1073156 · DOI
  32. Eisenhofer, 1996, Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans, J Neurochem, 66, 1565, 10.1046/j.1471-4159.1996.66041565.x · DOI · Paper page
  33. Dajani, 1999, X-ray crystal structure of human dopamine sulfotransferase, SULT1A3. Molecular modeling and quantitative structure-activity relationship analysis demonstrate a molecular basis for sulfotransferase substrate specificity, J Biol Chem, 274, 37862, 10.1074/jbc.274.53.37862 · DOI · Paper page
  34. Eisenhofer, 1999, Dopamine sulphate: an enigma resolved, Clin Exp Pharmacol Physiol Suppl, 26, S41
  35. Goldstein, 2003, Sources and significance of plasma levels of catechols and their metabolites in humans, J Pharmacol Exp Ther, 305, 800, 10.1124/jpet.103.049270 · DOI · Paper page
  36. Eisenhofer, 2022, Tietz Textbook of Laboratory Medicine, 319
  37. Goldstein, 1995, Is there a third peripheral catecholaminergic system? Endogenous dopamine as an autocrine/paracrine substance derived from plasma DOPA and inactivated by conjugation, Hypertens Res, 18, S93, 10.1291/hypres.18.SupplementI_S93 · DOI · Paper page
  38. Mezey, 1996, A novel nonneuronal catecholaminergic system: exocrine pancreas synthesizes and releases dopamine, Proc Natl Acad Sci U S A, 93, 10377, 10.1073/pnas.93.19.10377 · DOI · Paper page
  39. Eldrup, 1997, Effects of ordinary meals on plasma concentrations of 3,4-dihydroxyphenylalanine, dopamine sulphate and 3,4-dihydroxyphenylacetic acid, Clin Sci (Lond), 92, 423, 10.1042/cs0920423 · DOI · Paper page
  40. Mezey, 1999, Non-neuronal dopamine in the gastrointestinal system, Clin Exp Pharmacol Physiol Suppl, 26, S14
  41. Goldstein, 1999, Sources and physiological significance of plasma dopamine sulfate, J Clin Endocrinol Metab, 84, 2523, 10.1210/jcem.84.7.5864 · DOI · Paper page
  42. Brown, 1981, Renal conversion of plasma DOPA to urine dopamine, Br J Clin Pharmacol, 12, 251, 10.1111/j.1365-2125.1981.tb01210.x · doi:10.1111/j.1365-2125.1981.tb01210.x
  43. Wolfovitz, 1993, Derivation of urinary dopamine from plasma dihydroxyphenylalanine in humans, Clin Sci (Lond), 84, 549, 10.1042/cs0840549 · DOI · Paper page
  44. Baines, 1979, Tubular secretion and metabolism of dopamine, norepinephrine, methoxytyramine and normetanephrine by the rat kidney, J Pharmacol Exp Ther, 208, 144
  45. Eisenhofer, 2005, Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine, J Clin Endocrinol Metab, 90, 2068, 10.1210/jc.2004-2025 · DOI · Paper page
  46. Bennett, 1998, Sympathetic neuromuscular transmission at a varicosity in a syncytium, Microsc Res Tech, 42, 433, 10.1002/(SICI)1097-0029(19980915)42:6<433::AID-JEMT6>3.0.CO;2-N · doi:10.1002/(sici)1097-0029(19980915)42:6<433::aid-jemt6>3.0.co;2-n
  47. Marengo, 2018, How does the stimulus define exocytosis in adrenal chromaffin cells?, Pflugers Arch, 470, 155, 10.1007/s00424-017-2052-5 · DOI
  48. Axelrod, 1973, The fate of noradrenaline in the sympathetic neurone, Harvey Lect, 67, 175
  49. Eisenhofer, 1991, Neuronal re-uptake of noradrenaline by sympathetic nerves in humans, Clin Sci (Lond), 80, 257, 10.1042/cs0800257 · DOI · Paper page
  50. Bennett, 2005, A quantitative description of the contraction of blood vessels following the release of noradrenaline from sympathetic varicosities, J Theor Biol, 234, 107, 10.1016/j.jtbi.2004.11.013 · doi:10.1016/j.jtbi.2004.11.013
  51. Eisenhofer, 2008, Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma, Am J Physiol Endocrinol Metab, 295, E1223, 10.1152/ajpendo.90591.2008 · DOI · Paper page
  52. Hernandez-Guijo, 2000, Altered regulation of calcium channels and exocytosis in single human pheochromocytoma cells, Pflugers Arch, 440, 253, 10.1007/s004240000272 · DOI
  53. Ritchie, 1979, Catecholamine secretion in a rat pheochromocytoma cell line: two pathways for calcium entry, J Physiol, 286, 541, 10.1113/jphysiol.1979.sp012636 · doi:10.1113/jphysiol.1979.sp012636
  54. Eisenhofer, 2007, Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management, Drug Saf, 30, 1031, 10.2165/00002018-200730110-00004 · DOI
  55. Houy, 2022, Dysfunction of calcium-regulated exocytosis at a single-cell level causes catecholamine hypersecretion in patients with pheochromocytoma, Cancer Lett, 543, 10.1016/j.canlet.2022.215765 · DOI
  56. Levinson, 1983, Plasma norepinephrine and epinephrine responses to glucagon in patients with suspected pheochromocytomas, Metab Clin Exp, 32, 998, 10.1016/0026-0495(83)90142-7 · DOI
  57. Kawabe, 1985, Metoclopramide in the diagnosis of pheochromocytoma, Jpn Heart J, 26, 557, 10.1536/ihj.26.557 · doi:10.1536/ihj.26.557
  58. Ichikawa, 1985, Increase in blood pressure in pheochromocytoma induced by domperidone and metoclopramide, Tohoku J Exp Med, 146, 149, 10.1620/tjem.146.149 · doi:10.1620/tjem.146.149
  59. Lenders, 2010, Low sensitivity of glucagon provocative testing for diagnosis of pheochromocytoma, J Clin Endocrinol Metab, 95, 238, 10.1210/jc.2009-1850 · DOI
  60. Eisenhofer, 2011, Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma, Endocr Relat Cancer, 18, 97, 10.1677/ERC-10-0211 · DOI · Paper page
  61. Crout, 1964, Turnover and metabolism of catecholamines in patients with pheochromocytoma, J Clin Invest, 43, 94, 10.1172/JCI104898 · DOI · Paper page
  62. Ito, 1996, Pheochromocytomas: tendency to degenerate and cause paroxysmal hypertension, World J Surg, 20, 923, 10.1007/s002689900140 · doi:10.1007/s002689900140
  63. Eisenhofer, 1995, Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines, J Clin Endocrinol Metab, 80, 3009
  64. Gitlow, 1960, Diagnosis of pheochromocytoma by determination of urinary 3-methoxy-4-hydroxymandelic acid, J Clin Invest, 39, 221, 10.1172/JCI104022 · doi:10.1172/jci104022
  65. Von Euler, 1955, The urinary excretion of noradrenaline and Adrenaline in healthy subjects during recumbency and standing, Acta Physiol Scand, 34, 169, 10.1111/j.1748-1716.1955.tb01237.x · doi:10.1111/j.1748-1716.1955.tb01237.x
  66. Weil-Malherbe, 1957, The estimation of catecholamines in urine by a chemical method, J Clin Pathol, 10, 138, 10.1136/jcp.10.2.138 · doi:10.1136/jcp.10.2.138
  67. Manger, 1969, Comparison of improved fluorometric methods used to quantitate plasma catecholamines, Clin Chem, 15, 1101, 10.1093/clinchem/15.12.1101 · doi:10.1093/clinchem/15.12.1101
  68. Bravo, 1979, Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications, N Engl J Med, 301, 682, 10.1056/NEJM197909273011302 · DOI · Paper page
  69. Moyer, 1979, Analysis for urinary catecholamines by liquid chromatography with amperometric detection: methodology and clinical interpretation of results, Clin Chem, 25, 256, 10.1093/clinchem/25.2.256 · DOI · Paper page
  70. Pisano, 1960, A simple analysis of normetanephrine and metanephrine in urine, Clin Chem, 5, 406, 10.1016/0009-8981(60)90146-7 · DOI · Paper page
  71. Davidson, 2002, Phaeochromocytoma with normal urinary catecholamines: the potential value of urinary free metadrenalines, Ann Clin Biochem, 39, 557, 10.1177/000456320203900603 · DOI · Paper page
  72. Boyle, 2007, Comparison of diagnostic accuracy of urinary free metanephrines VMA, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma, J Clin Endocrinol Metab, 92, 4602, 10.1210/jc.2005-2668 · DOI · Paper page
  73. Zuo, 2018, High specificity of spot urinary free metanephrines in diagnosis and prognosis of pheochromocytomas and paragangliomas by HPLC with electrochemical detection, Clin Chim Acta, 478, 82, 10.1016/j.cca.2017.12.026 · DOI
  74. Peitzsch, 2020, Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?, Eur J Endocrinol, 182, 499, 10.1530/EJE-19-1016 · doi:10.1530/eje-19-1016
  75. Wang, 2020, Detection of spot urinary free metanephrines and 3-methoxytyramine with internal reference correction for the diagnosis of pheochromocytomas and paragangliomas, J Chromatogr B Analyt Technol Biomed Life Sci, 1156, 10.1016/j.jchromb.2020.122306 · DOI
  76. Ahn, 2021, Urinary free metanephrines for diagnosis of pheochromocytoma and paraganglioma, Endocrinol Metab (Seoul), 36, 697, 10.3803/EnM.2020.925 · DOI
  77. Eisenhofer, 2012, Rapid circulatory clearances and half-lives of plasma free metanephrines, Clin Endocrinol (Oxf), 77, 484, 10.1111/j.1365-2265.2012.04340.x · DOI
  78. Osinga, 2016, Mass spectrometric quantification of salivary metanephrines-a study in healthy subjects, Clin Biochem, 49, 983, 10.1016/j.clinbiochem.2016.02.003 · DOI
  79. Kobayashi, 1980, A radioenzymatic assay for plasma normetanephrine in man and patients with pheochromocytoma, Life Sci, 26, 567, 10.1016/0024-3205(80)90321-5 · doi:10.1016/0024-3205(80)90321-5
  80. Lenders, 1993, Determination of metanephrines in plasma by liquid chromatography with electrochemical detection, Clin Chem, 39, 97, 10.1093/clinchem/39.1.97 · DOI · Paper page
  81. Weismann, 2015, Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma, Eur J Endocrinol, 172, 251, 10.1530/EJE-14-0730 · DOI · Paper page
  82. O’Connor, 1984, Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma, N Engl J Med, 311, 764, 10.1056/NEJM198409203111204 · DOI · Paper page
  83. Madhavaram, 2014, Interference from Indian diet on the internal standard in a commercial method for the measurement of urinary metanephrines by high-performance liquid chromatography with electrochemical detection, Ann Clin Biochem, 51, 400, 10.1177/0004563213494079 · doi:10.1177/0004563213494079
  84. Emms, 2018, Falsely elevated plasma metanephrine in patients taking midodrine, Ann Clin Biochem, 55, 509, 10.1177/0004563218755817 · DOI
  85. Dunand, 2014, Analytical interference of 4-hydroxy-3-methoxymethamphetamine with the measurement of plasma free normetanephrine by ultra-high pressure liquid chromatography-tandem mass spectrometry, Clin Biochem, 47, 1121, 10.1016/j.clinbiochem.2014.04.003 · doi:10.1016/j.clinbiochem.2014.04.003
  86. Wright, 2015, Multiple reaction monitoring with multistage fragmentation (MRM3) detection enhances selectivity for LC-MS/MS analysis of plasma free metanephrines, Clin Chem, 61, 505, 10.1373/clinchem.2014.233551 · DOI
  87. Peitzsch, 2015, Interference from 3-O-methyldopa with ultra-high performance LC-MS/MS measurements of plasma metanephrines: chromatographic separation remains important, Clin Chem, 61, 993, 10.1373/clinchem.2015.239962 · doi:10.1373/clinchem.2015.239962
  88. Davies, 2019, Liquid chromatography tandem mass spectrometry for plasma metadrenalines, Clin Chim Acta, 495, 512, 10.1016/j.cca.2019.05.024 · DOI
  89. Gardet, 2001, Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma, J Hypertens, 19, 1029, 10.1097/00004872-200106000-00006 · DOI
  90. Kobayashi, 1978, Interference with fluorimetric assay of catecholamine by labetalol, Tohoku J Exp Med, 126, 201, 10.1620/tjem.126.201 · doi:10.1620/tjem.126.201
  91. Pillai, 1991, Quality assurance for biogenic amines with authentic patient specimens, Pathology, 23, 11, 10.3109/00313029109061432 · doi:10.3109/00313029109061432
  92. Bouloux, 1985, Interference of labetalol metabolites in the determination of plasma catecholamines by HPLC with electrochemical detection, Clin Chim Acta, 150, 111, 10.1016/0009-8981(85)90261-X · doi:10.1016/0009-8981(85)90261-x
  93. Davidson, 1988, Urinary catecholamine assay by HPLC: in vitro interference by some drugs, Ann Clin Biochem, 25, 583, 10.1177/000456328802500517 · doi:10.1177/000456328802500517
  94. Wilson, 1985, Acetaminophen administration interferes with urinary metanephrine (and catecholamine) determinations, Clin Chem, 31, 1093, 10.1093/clinchem/31.6.1093 · doi:10.1093/clinchem/31.6.1093
  95. Davidson, 2004, Paracetamol-associated interference in an HPLC-ECD assay for urinary free metadrenalines and catecholamines, Ann Clin Biochem, 41, 316, 10.1258/0004563041201626 · DOI
  96. Ito, 2006, Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result, Surg Today, 36, 961, 10.1007/s00595-006-3291-9 · DOI
  97. Bouhanick, 2010, Biochemical misdiagnosis of pheochromocytoma in patients treated with sulfasalazine, JAMA, 304, 1898, 10.1001/jama.2010.1563 · DOI
  98. Joyce, 2020, Case report of a phantom pheochromocytoma, Biochem Med (Zagreb), 30, 10.11613/BM.2020.021003 · DOI
  99. Barco, 2014, Amoxicillin-associated interference in an HPLC-EC assay for urinary fractionated metanephrines: potential pitfall in pheochromocytoma biochemical diagnosis, Clin Biochem, 47, 119, 10.1016/j.clinbiochem.2014.07.009 · doi:10.1016/j.clinbiochem.2014.07.009
  100. Kim, 2015, Rifampicin interference in the measurement of urinary catecholamines by high-performance liquid chromatography, Ann Clin Lab Sci, 45, 356
  101. van Laarhoven, 2004, Pitfall in HPLC assay for urinary metanephrines: an unusual type of interference caused by methenamine intake, Clin Chem, 50, 1097, 10.1373/clinchem.2004.032912 · DOI
  102. Gitlow, 1970, The biochemical techniques for detecting and establishing the presence of a pheochromocytoma. A review of ten years’ experience, Am J Cardiol, 26, 270, 10.1016/0002-9149(70)90794-0 · DOI
  103. Oishi, 1980, Random one-hour urine catecholamine and 4-hydroxy-3-methoxymandelic acid assays for diagnosis of pheochromocytoma, Clin Chim Acta, 103, 335, 10.1016/0009-8981(80)90152-7 · doi:10.1016/0009-8981(80)90152-7
  104. Peaston, 1993, Biochemical detection of phaeochromocytoma: should we still be measuring urinary HMMA?, J Clin Pathol, 46, 734, 10.1136/jcp.46.8.734 · DOI · Paper page
  105. Gerlo, 1994, Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases, Clin Chem, 40, 250, 10.1093/clinchem/40.2.250 · DOI · Paper page
  106. Mannelli, 1987, Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma, J Endocrinol Invest, 10, 377, 10.1007/BF03348153 · DOI
  107. Havlik, 1988, Advances in the diagnosis and treatment of pheochromocytoma, Arch Surg, 123, 626, 10.1001/archsurg.1988.01400290112020 · DOI
  108. Smythe, 1992, Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine, Clin Chem, 38, 486, 10.1093/clinchem/38.4.486 · doi:10.1093/clinchem/38.4.486
  109. Duncan, 1988, Measurement of norepinephrine and 3,4-dihydroxyphenylglycol in urine and plasma for the diagnosis of pheochromocytoma, N Engl J Med, 319, 136, 10.1056/NEJM198807213190303 · DOI · Paper page
  110. Ganguly, 1979, Diagnosis and localization of pheochromocytoma. Detection by measurement of urinary norepinephrine excretion during sleep, plasma norepinephrine concentration and computerized axial tomography (CT-scan), Am J Med, 67, 21, 10.1016/0002-9343(79)90064-0 · DOI
  111. Mannelli, 1989, Diagnostic problems in pheochromocytoma, J Endocrinol Invest, 12, 739, 10.1007/BF03350050 · DOI
  112. Sinclair, 1991, Normal catecholamine production in a patient with a paroxysmally secreting phaeochromocytoma, Ann Clin Biochem, 28, 417, 10.1177/000456329102800420 · DOI
  113. Enat, 1991, Catecholamine determination in sequential urine voiding: a method for detecting pheochromocytoma in patients without elevated urinary catecholamines, Isr J Med Sci, 27, 12
  114. Ross, 1993, Plasma and 24 hours-urinary catecholamine concentrations in normal and patient populations, Ann Clin Biochem, 30, 38, 10.1177/000456329303000107 · DOI
  115. Stewart, 1993, Biochemical diagnosis of phaeochromocytoma: two instructive case reports, J Clin Pathol, 46, 280, 10.1136/jcp.46.3.280 · DOI · Paper page
  116. Lenders, 1995, Plasma metanephrines in the diagnosis of pheochromocytoma, Ann Intern Med, 123, 101, 10.7326/0003-4819-123-2-199507150-00004 · DOI · Paper page
  117. Raber, 2000, Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma, Arch Intern Med, 160, 2957, 10.1001/archinte.160.19.2957 · DOI · Paper page
  118. Unger, 2006, Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass, Eur J Endocrinol, 154, 409, 10.1530/eje.1.02097 · DOI · Paper page
  119. Manu, 1984, Biochemical screening for pheochromocytoma. Superiority of urinary metanephrines measurements, Am J Epidemiol, 120, 788, 10.1093/oxfordjournals.aje.a113947 · DOI
  120. Hernandez, 2000, A five-year report on experience in the detection of pheochromocytoma, Clin Biochem, 33, 649, 10.1016/S0009-9120(00)00172-7 · DOI
  121. Young, 1989, Biochemical tests for pheochromocytoma: strategies in hypertensive patients, J Gen Intern Med, 4, 273, 10.1007/BF02597394 · DOI
  122. Heron, 1996, The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma, Ann Intern Med, 125, 300, 10.7326/0003-4819-125-4-199608150-00008 · DOI · Paper page
  123. Brain, 2006, Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population, Clin Chem, 52, 2060, 10.1373/clinchem.2006.070805 · DOI · Paper page
  124. Grouzmann, 2010, Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma, Eur J Endocrinol, 162, 951, 10.1530/EJE-09-0996 · DOI · Paper page
  125. Davidson, 2012, Urinary free (unconjugated) metadrenalines in different hereditary forms of catecholamine-secreting phaeochromocytoma/paraganglioma, Ann Clin Biochem, 49, 486, 10.1258/acb.2012.012021 · DOI
  126. Perry, 2007, The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma, Clin Endocrinol (Oxf), 66, 703, 10.1111/j.1365-2265.2007.02805.x · DOI · Paper page
  127. Lenders, 2002, New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines, Ann N Y Acad Sci, 970, 29, 10.1111/j.1749-6632.2002.tb04410.x · DOI
  128. Vaclavik, 2007, Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients, J Hypertens, 25, 1427, 10.1097/HJH.0b013e32813aeb5a · DOI · Paper page
  129. Hickman, 2009, Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma, Pathology, 41, 173, 10.1080/00313020802579284 · DOI
  130. Peaston, 2010, Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma, Clin Chim Acta, 411, 546, 10.1016/j.cca.2010.01.012 · DOI
  131. Kim, 2015, Diagnostic accuracy of plasma free metanephrines in a seated position compared with 24-hour urinary metanephrines in the investigation of pheochromocytoma, Endocr J, 62, 243, 10.1507/endocrj.EJ14-0384 · DOI · Paper page
  132. Boot, 2017, Single-centre study of the diagnostic performance of plasma metanephrines with seated sampling for the diagnosis of phaeochromocytoma/paraganglioma, Ann Clin Biochem, 54, 143, 10.1177/0004563216650463 · DOI
  133. Gao, 2008, Comparison of free plasma metanephrines enzyme immunoassay with (131)I-MIBG scan in diagnosis of pheochromocytoma, Clin Exp Med, 8, 87, 10.1007/s10238-008-0162-2 · DOI
  134. Mullins, 2011, Enzyme-linked immunoassay for plasma-free metanephrines in the biochemical diagnosis of phaeochromocytoma in adults is not ideal, Clin Chem Lab Med, 50, 105
  135. Sarathi, 2011, Performance of fractionated plasma free metanephrines by enzyme immunoassay in the diagnosis of pheochromocytoma and paraganglioma, Endocr Pract, 17, 759, 10.4158/EP11058.OR · DOI
  136. Christensen, 2011, Comparison of plasma metanephrines measured by a commercial immunoassay and urinary catecholamines in the diagnosis of pheochromocytoma, Scand J Clin Lab Invest, 71, 695, 10.3109/00365513.2011.622410 · DOI
  137. Unger, 2012, Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass, Exp Clin Endocrinol Diabetes, 120, 494, 10.1055/s-0032-1309007 · DOI · Paper page
  138. Raber, 2020, Measurements of plasma-free metanephrines by immunoassay versus urinary metanephrines and catecholamines by liquid chromatography with amperometric detection for the diagnosis of pheochromocytoma/paraganglioma, J Clin Med, 9, 3108, 10.3390/jcm9103108 · DOI
  139. Patin, 2016, Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas, Clin Biochem, 49, 1205, 10.1016/j.clinbiochem.2016.05.008 · DOI
  140. Wang, 2020, Stability and reference intervals of spot urinary fractionated metanephrines and methoxytyramine by tandem mass spectrometry as a screening method for pheochromocytoma and paraganglioma, Endocrine, 69, 188, 10.1007/s12020-020-02267-8 · DOI
  141. Eijkelenkamp, 2021, Diagnostic accuracy of salivary metanephrines in pheochromocytomas and paragangliomas, Clin Chem, 67, 1090, 10.1093/clinchem/hvab064 · DOI
  142. Timmers, 2008, Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene, J Clin Endocrinol Metab, 93, 4826, 10.1210/jc.2008-1093 · DOI · Paper page
  143. Heavner, 2015, Pheochromocytoma diagnosed pathologically with previous negative serum markers, J Surg Oncol, 112, 492, 10.1002/jso.24031 · DOI
  144. Richter, 2022, Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine, Endocr Relat Cancer, 29, 213, 10.1530/ERC-21-0359 · DOI
  145. Tischler, 2008, Pheochromocytoma and extra-adrenal paraganglioma: updates, Arch Pathol Lab Med, 132, 1272, 10.5858/2008-132-1272-PAEPU · DOI · Paper page
  146. Constantinescu, 2022, Silent pheochromocytoma and paraganglioma: systematic review and proposed definitions for standardized terminology, Front Endocrinol (Lausanne), 13, 10.3389/fendo.2022.1021420 · DOI
  147. Blaschko, 1967, Secretion of a chromaffin granule protein, chromogranin, from the adrenal gland after splanchnic stimulation, Nature, 215, 58, 10.1038/215058a0 · DOI · Paper page
  148. Modlin, 2010, Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease, Ann Surg Oncol, 17, 2427, 10.1245/s10434-010-1006-3 · DOI · Paper page
  149. Hofland, 2018, Role of biomarker tests for diagnosis of neuroendocrine tumours, Nat Rev Endocrinol, 14, 656, 10.1038/s41574-018-0082-5 · DOI
  150. Marotta, 2018, Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame, Endocr Relat Cancer, 25, R11, 10.1530/ERC-17-0269 · DOI · Paper page
  151. Hsiao, 1991, Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma, Medicine (Baltimore), 70, 33, 10.1097/00005792-199101000-00003 · DOI · Paper page
  152. Canale, 1994, Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction, J Clin Endocrinol Metab, 78, 1139
  153. Stridsberg, 1997, Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma, Eur J Endocrinol, 136, 67, 10.1530/eje.0.1360067 · DOI · Paper page
  154. Nobels, 1997, Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones, J Clin Endocrinol Metab, 82, 2622
  155. d’Herbomez, 2001, Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma, J Nucl Med, 42, 993
  156. Grossrubatscher, 2006, The role of chromogranin A in the management of patients with phaeochromocytoma, Clin Endocrinol (Oxf), 65, 287, 10.1111/j.1365-2265.2006.02591.x · DOI
  157. Giovanella, 2006, Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan, Q J Nucl Med Mol Imaging, 50, 344
  158. Bilek, 2019, Chromogranin A in the laboratory diagnosis of pheochromocytoma and paraganglioma, Cancers (Basel), 11, 586, 10.3390/cancers11040586 · DOI
  159. Cleary, 2007, Chromogranin A expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2, Horm Metab Res, 39, 876, 10.1055/s-2007-993135 · doi:10.1055/s-2007-993135
  160. Zuber, 2014, Clinical utility of chromogranin A in SDHx-related paragangliomas, Eur J Clin Invest, 44, 365, 10.1111/eci.12245 · DOI
  161. Rao, 2000, Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment, Hypertension, 36, 1045, 10.1161/01.HYP.36.6.1045 · DOI · Paper page
  162. van Duinen, 2011, Plasma chromogranin A levels are increased in a small portion of patients with hereditary head and neck paragangliomas, Clin Endocrinol (Oxf), 74, 160, 10.1111/j.1365-2265.2010.03914.x · DOI
  163. Algeciras-Schimnich, 2008, Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma, J Clin Endocrinol Metab, 93, 91, 10.1210/jc.2007-1354 · DOI · Paper page
  164. Liu, 2022, Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: which is the best diagnostic strategy, Clin Endocrinol (Oxf), 96, 132, 10.1111/cen.14585 · DOI
  165. Plouin, 2016, European Society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma, Eur J Endocrinol, 174, G1, 10.1530/EJE-16-0033 · DOI · Paper page
  166. O’Connor, 1986, Secretion of chromogranin A by peptide-producing endocrine neoplasms, N Engl J Med, 314, 1145, 10.1056/NEJM198605013141803 · DOI · Paper page
  167. Blind, 1992, Chromogranin A as tumor marker in medullary thyroid carcinoma, Thyroid, 2, 5, 10.1089/thy.1992.2.5 · DOI · Paper page
  168. Lawrence, 2011, The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors, Endocrinol Metab Clin North Am, 40, 111, 10.1016/j.ecl.2010.12.001 · DOI · Paper page
  169. Kadmon, 1991, Elevated plasma chromogranin-A concentrations in prostatic carcinoma, J Urol, 146, 358, 10.1016/S0022-5347(17)37793-5 · DOI · Paper page
  170. Spadaro, 2005, Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits, World J Gastroenterol, 11, 1987, 10.3748/wjg.v11.i13.1987 · DOI · Paper page
  171. Massironi, 2009, Chromogranin A levels in chronic liver disease and hepatocellular carcinoma, Dig Liver Dis, 41, 31, 10.1016/j.dld.2008.05.002 · DOI
  172. Sanduleanu, 1999, Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study, Aliment Pharmacol Ther, 13, 145, 10.1046/j.1365-2036.1999.00466.x · DOI · Paper page
  173. Waldum, 2001, Serum chromogranin A in the control of patients on long-term treatment with inhibitors of acid secretion, Eur J Clin Invest, 31, 741, 10.1046/j.1365-2362.2001.00889.x · DOI
  174. O’Connor, 1989, Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure, Clin Chem, 35, 1631, 10.1093/clinchem/35.8.1631 · DOI · Paper page
  175. Hsiao, 1990, Chromogranin A in uremia: progressive retention of immunoreactive fragments, Kidney Int, 37, 955, 10.1038/ki.1990.71 · DOI
  176. Ceconi, 2002, Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality, Eur Heart J, 23, 967, 10.1053/euhj.2001.2977 · DOI · Paper page
  177. Sciola, 2009, Plasma chromogranin a in patients with inflammatory bowel disease, Inflamm Bowel Dis, 15, 867, 10.1002/ibd.20851 · DOI · Paper page
  178. Stridsberg, 2003, A comparison between three commercial kits for chromogranin A measurements, J Endocrinol, 177, 337, 10.1677/joe.0.1770337 · DOI · Paper page
  179. Giovanella, 2010, Spurious increase in serum chromogranin A: the role of heterophilic antibodies, Clin Chem Lab Med, 48, 1497, 10.1515/CCLM.2010.293 · DOI
  180. Willemsen, 2003, Stability of plasma free metanephrines during collection and storage as assessed by an optimized HPLC method with electrochemical detection, Clin Chem, 49, 1951, 10.1373/clinchem.2003.023135 · DOI · Paper page
  181. Danese, 2020, Short-term stability of free metanephrines in plasma and whole blood, Clin Chem Lab Med, 58, 753, 10.1515/cclm-2019-0020 · DOI
  182. Wang, 2021, Study of stability and interference for catecholamines and metanephrines, 3-methoxytyramine: key point of an accurate diagnosis for pheochromocytoma and paraganglioma, Scand J Clin Lab Invest, 81, 564, 10.1080/00365513.2021.1980901 · doi:10.1080/00365513.2021.1980901
  183. Yu, 2021, Plasma or serum, which is the better choice for the measurement of metanephrines?, Scand J Clin Lab Invest, 81, 250, 10.1080/00365513.2021.1904280 · DOI
  184. Deutschbein, 2010, Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma, Clin Endocrinol (Oxf), 73, 153, 10.1111/j.1365-2265.2009.03761.x · DOI · Paper page
  185. Peitzsch, 2016, Preservation of urine free catecholamines and their free O-methylated metabolites with citric acid as an alternative to hydrochloric acid for LC-MS/MS-based analyses, Clin Chem Lab Med, 54, 37, 10.1515/cclm-2015-0044 · DOI
  186. Musson, 2018, Omission of preservatives during 24-h of urine collection for the analysis of fractionated metanephrines enhance patient convenience, Clin Chem Lab Med, 56, e306, 10.1515/cclm-2018-0474 · DOI
  187. Pinto, 2020, No effect of acidification or freezing on urinary metanephrine levels, J Endocrinol Invest, 43, 53, 10.1007/s40618-019-01076-9 · DOI
  188. Eugster, 2021, Stabilization of urinary biogenic amines measured in clinical chemistry laboratories, Clin Chim Acta, 514, 24, 10.1016/j.cca.2020.12.009 · DOI
  189. Goldstein, 2013, Differential responses of components of the autonomic nervous system, Handb Clin Neurol, 117, 13, 10.1016/B978-0-444-53491-0.00002-X · DOI
  190. Schmidt, 1996, Beta-endorphin and catecholamine concentrations during chronic and acute stress in intensive care patients, Eur J Med Res, 1, 528
  191. Nadeau, 1979, Plasma catecholamines in acute myocardial infarction, Am Heart J, 98, 548, 10.1016/0002-8703(79)90278-3 · DOI
  192. McCance, 1989, Selective enhancement of the cardiac sympathetic response to exercise by anginal chest pain in humans, Circulation, 80, 1642, 10.1161/01.CIR.80.6.1642 · DOI
  193. Schatz, 1982, Mitral valve prolapse: association with bizarre behavior, a confusional state, and aphasia, Arch Intern Med, 142, 1215, 10.1001/archinte.1982.00340190171028 · doi:10.1001/archinte.1982.00340190171028
  194. Jensterle, 2022, Comparison of plasma metanephrines in patients with cyanotic and acyanotic congenital heart disease, Endocrine, 78, 580, 10.1007/s12020-022-03205-6 · DOI
  195. Robertson, 1979, Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man, Circulation, 59, 637, 10.1161/01.CIR.59.4.637 · DOI · Paper page
  196. Meyer, 1973, Catecholamine concentrations in CSF and plasma of patients with cerebral infarction and haemorrhage, Brain, 96, 277, 10.1093/brain/96.2.277 · DOI · Paper page
  197. Jansen, 1988, Blood pressure and both venous and urinary catecholamines after cerebral infarction, Clin Neurol Neurosurg, 90, 41, 10.1016/S0303-8467(88)80008-8 · doi:10.1016/s0303-8467(88)80008-8
  198. Hamann, 1995, Pattern of elevation of urine catecholamines in intracerebral haemorrhage, Acta Neurochir (Wien), 132, 42, 10.1007/BF01404846 · doi:10.1007/bf01404846
  199. Lamotte, 2021, Natural history of afferent baroreflex failure in adults, Neurology, 97, e136, 10.1212/WNL.0000000000012149 · DOI
  200. Metz, 1978, Autonomic epilepsy: clonidine blockade of paroxysmal catecholamine release and flushing, Ann Intern Med, 88, 189, 10.7326/0003-4819-88-2-189 · DOI

200 of 426 shown

Metadata

Authors
Eisenhofer, G., Pamporaki, C., & Lenders, J. W. M.
Venue
Endocrine Reviews
Published
2023-03-30
Volume
44
Issue
5
Pages
862-909
ISSN
  • 0163-769X
  • 1945-7189
Cited by
116
References
22
Language
en
Funders
Deutsche Forschungsgemeinschaft

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biochemical Assessment of Pheochromocytoma and Paraganglioma. https://app.cochat.ai/papers/10.1210/endrev/bnad011
The paper
Eisenhofer, G., Pamporaki, C., & Lenders, J. W. M. (2023). Biochemical Assessment of Pheochromocytoma and Paraganglioma. Endocrine Reviews. https://doi.org/10.1210/endrev/bnad011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.